sage of Dapagliflozin in the management of Type-2 Diabetes Mellitus in Indian patients
Not Applicable
Completed
- Conditions
- Health Condition 1: null- Type 2 Diabetes
- Registration Number
- CTRI/2017/03/008011
- Lead Sponsor
- AstraZeneca Pharma India Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Patients who provide written informed consent.
2. Patients with previously diagnosed Type-2 diabetes mellitus
3. Patients with inadequately controlled diabetes (HbA1c >7%) with existing anti-diabetic medications, prior to initiation of dapagliflozin treatment.
4. Patients who are taking dapagliflozin within last 3 months.
5.Patients who are having past medical records for demographic information, weight, blood pressure and HbA1c value at the time of dapagliflozin prescribed
Exclusion Criteria
1.Patients with Type-1 diabetes mellitus
2. Patients with any medical condition which in the opinion of the investigator would interfere with safe completion of the study
3. Pregnant or lactating women
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Mean change in HbA1CTimepoint: 6 month
- Secondary Outcome Measures
Name Time Method Mean change in weight and BPTimepoint: 6 month